Browse Studies — Arctuva

Phase 3

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with n…

Low Grade AstrocytomaLow Grade GliomaMetastatic Low Grade Astrocytoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04166409

Phase 1

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has c…

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more

Estimated

~$10 – $6,250

Northwestern UniversityNCT06410248

Phase 1

A Phase I, Dose-Escalation Trial of Anti-GARP Chimeric Antigen Receptor-T Cell Therapy in Patients With Recurrent High-Grade Glioma Treated at a Single Medical Center

This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell t…

Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 Glioma+3 more

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT06964737